Lumanity



Lumanity at ISPOR Europe 2025

From caregiver quality of life to innovations in survival modeling, our experts are shaping conversations that drive better healthcare decisions.

Glasgow
November 9-12
Booth 720

Issue Panel

Wednesday November 12 | 08:00 – 09:00 (GMT)

Traditional and emerging methods for including caregiver's health-related quality of life in economic evaluation: can we reconcile modelling assumptions with caregivers' experiences?

Ron Akehurst (Moderator), Fleur Chandler, Becky Pennington, Erik Landfeldt

Workshop

Wednesday, November 12 | 08:00 – 09:00 (GMT)

Taking a Time-out to Understand Innovations in Survival Modeling: A Practical and Open Discussion of Time-Varying Network Meta-Analyses (NMA) Informing Cost-Effectiveness Models (CEM) and Health Technology Assessments (HTA)

Yu-Heng Liu, Benjamin C Kearns, Hugo Pedder, Tracy Westley

Posters

Monday, November 10 | Poster Session 1 | 10:30 – 13:30 (GMT)

Association Between Invasive Disease-free Survival/Distant Recurrence-free Survival and Overall Survival in Patients With Early-Stage Triple-Negative Breast Cancer

Aurelien Jamotte, Jagadeswara Rao Earla, **Ketsia Habimana**, Jane Candlish, **Amit Ahuja, Sakshi Jindal, Kanupriya Mahajan, Aniket Sharma,** Ioana Gulas, Tracy Westley, Peter Fasching

Network Meta-analysis for an Efficacy Assessment of Avelumab + Axitinib in the First-Line Treatment of International Metastatic RCC Database Consortium (IMDC) Favorable Risk Patients With Advanced Renal Cell Carcinoma (ARCC)

Mairead Kearney, Anna-Maria Fontrier, Tina Alexopoulos, **Yu-Heng Liu, Neil Roskell**

Budget and Time Impact Analysis of Introducing Subcutaneous Pembrolizumab to Patients From Institution HCP and Patient Perspectives in the United States US

Ying Xiao, Sabine Oskar, **Spencer Notinger, Colin Burke, Karl Patterson**, Jingshu Wang

Content Validation of a Modified PozQoL for Assessing HIV Therapies

Karine Dube, Sorana Segal-Maurer, Martin Duracinsky, **Martha Gauthier, Kathy Vong, Harlow Sharp, Blaise Cureg, Imani Weeks,** Kwanza Price, Caroline Burk, James Jarrett

Monday, November 10 | Poster Session 2 | 16:00 – 19:00 (GMT)

Conceptual Approach to Economic Modelling in Retinal Diseases: A Review and Critique of Two NICE Clinical Guidelines

Chrissy Lowry, Karl Patterson, Edward Church

Cost-Effectiveness of First-Line Lorlatinib for ALK-Positive Advanced NSCLC in the UK

Daniel Ladino, Victoria Brodbin, **Carina Marie Behr, Ian Gould**, Hannah Le

Epidemiology of Wilsons Disease in Europe: A Literature Review

Rishabh Verma, Amit Ahuja

Epidemiology and Outcomes in a Linked Cohort of Cancer, Pathology and Electronic Medical Records from the PHARMO Data Network

Nikita Jeswani, Ellie Iob, Naomi Reimes, Josine Kuiper, Rinus Voorham

Development of Two Versions of a Patient-Preference Questionnaire for Evaluating Potential HIV Cure-Related and Other HIV Interventions

Karine Dube, Sorana Segal-Maurer, Martin Duracinsky, **Martha Gauthier, Kathy Vong, Harlow Sharp, Blaise Cureg, Imani Weeks**, Kwanza Price, Caroline Burk, James Jarrett

Tuesday, November 11 | Poster Session 3 | 10:30–13:30 (GMT)

Health Technology Assessment landscape for medical devices in Europe

Laure Weijers, Michelle Smith, Chantelle Browne

Identifying Risk Factors Associated with Meningioma: A Systematic Review

Vyshnavi Telukuntla, Sumi Pillai, Nidhun Kandoth, Sukannya Mahapatra, Ankit Rohilla, Inderpreet Singh Khurana

Health-Related Quality of Life in Patients Living with Osteosarcoma in Europe: A Systematic Review

Taruni Priya Donkana, Vyshnavi Telukuntla, Amit Ahuja, Aisha Agrawal Goyal, Jyoti Garg

Economic Burden of Gaucher Disease: A Systematic Literature Review

Aikyadeep Mandal, Taruni Priya Donkana, Jyoti Garg, Amit Ahuja

Economic Evaluation of Bispecific Antibodies in Europe: A Systematic Review

Debjit Ghoshal, Prakhar Lambhate, Sumi Pillai, Tanya Madan

Impact of Individualized Neoantigen Therapies on Health, Productivity and Health System Capacity Outcomes in Resected Melanoma in Belgium

Chien-Jhih Tsai, Izzy Thornton, Catarina Neves, Cedric Boucherie, André Bento Abreu, Ying Xiao, Christopher Black

Evaluating the Health Impact of Anti-PD-1 Agents for Early-Stage Cancer Treatment in the Czech Republic

Gittan Blezer, Karl Patterson, Tomas Mlcoch, Jana Alahakoon, Joyce Yizhen Lai, Vivek Khurana, Raquel Aguiar-Ibáñez

Identification of Real-World Data to Study Hereditary Angioedema Unmet Need: A Targeted Literature Review

Temitope Adebayo-Ojo, Mateo Delclaux Rodriguez-Rey, Meena Venkatachalam, Madeleine Thursfield, Charlotte Heeks

Tuesday, November 11 | Poster Session 4 | 16:00–19:00 (GMT)

Recent Changes in HTA and Reimbursement Requirements: Learnings for Global Dossiers

Catherine Rycroft, Benjamin Farrar

Routing Decisions and Outcomes of NICE Technology Appraisals under Proportionate Approach to Technology Appraisals

Carina Behr, Ewa Rupniewska, Stuart Gaines, Ayesha Qureshi, Sallie Latimer

Role of Technical Engagement in NICE process under Proportionate Approach to Technology Appraisals

Ewa Rupniewska, Carina Behr, Stuart Gaines, Ayesha Qureshi, Sallie Latimer

Non-proportional Hazards Network Meta-Analysis in NICE Technology Appraisals – Prevalence and Insights

Yan Zhi Tan, Yu-Heng Liu, Autumn Hoang, Alessandro Catanzaro, Yi Hsuan Chen, Benjamin Kearns, Tracy Westley

Prognostic factor evaluation for clinical outcomes in HER2-mutant NSCLC

Heiko Zettl, Lorenz Uhlmann, Stephan Herbertz, **Emma Tyas, Neil Roskell**

Studying paternal drug exposures and offspring outcomes: a feasibility assessment of 11 large European databases

Sandrine Colas, Hillary Bonnet, Laurie Fraticelli, Emmanuelle Bignon, Jérémy Jové, Vera Ehrenstein, Maria Giner-Soriano, Jonas Reinold, Wiebke Schäfer, Anna-Maija Tolppanen, Carolyn Cesta, Jacqueline Cohen, Romin Pajouheshnia, **Josine Kuiper*, Eline Houben*,** Marie-Laure Kürzinger, Juliette Longin, Laure Carcaillon-Bentata

**PHARMO, Part of Lumanity*

Wednesday, November 12 | Poster Session 5 | 09:00–11:30 (GMT)

Treatment Discontinuation in Idiopathic Pulmonary Fibrosis: A Systematic Review of Antifibrotic Drug Use and Tolerability

Sukannya Mahapatra, Nidhun Kandoth, Vyshnavi Telukuntla, Ankit Rohilla, Inderpreet Singh Khurana

Using Structured Expert Elicitation to Estimate Long-term Organ Damage Risk in an Ultra-rare Condition: A STEER Case Study

Amie Padhiar, **Colin Burke**, Mathilde Puls, Annie Berkley, **Oliver Heard, Harold Wolff,** Linda Murphy, Harneet Kaur

Development of Two Versions of a Patient-Reported Outcome Measure to Evaluate Participant Experience and Satisfaction During the Intervention and Analytical Treatment Interruption Periods of Cure-Related and Other HIV Trials

Karine Dube, Sorana Segal-Maurer, Martin Duracinsky, **Martha Gauthier, Kathy Vong, Harlow Sharp, Imani Weeks**, Kwanza Price, Caroline Burk, James Jarrett

Population Impact of Performing BRCA1/2 Testing to Guide Metastatic Castration-Resistant Prostate Cancer Treatment in Spain

Federico Rojo, Elena Castro, David Olmos, Virginia Lozano Rosas, Belen Sanz, Melissa Kirker, Allison Thompson, Neo Su, **Yang Meng, Annika Bjerke, Divya Patil,** Joaquin Mateo

Systematic Literature Review (SLR) of First-Line (1L) Treatments of Patients With Advanced or Metastatic HER2-Positive Gastroesophageal Adenocarcinoma (GEA)

John Bridgewater, Javier Sabater, Junji Lin, Wayne Su, **Tanya Madan, Paranjoy Saharia, Michelle Smith**